XML 66 R54.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Royalty and Commercial Payment Purchase Agreements - Affitech (Details) - USD ($) |  | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | --- | ---
Oct. 06, 2021 | Jan. 31, 2022 | Mar. 31, 2024 | Mar. 31, 2023 | Dec. 31, 2023
Agreements |  |  |  |  |
Payments of consideration under RPAs, AAAs and CPPAs |  |  | $ 15,000,000 | $ 9,600,000 |
Contingent consideration under RPAs, AAAs and CPPAs |  |  | 3,000,000 |  | $ 7,000,000
Receipts under RPAs, AAAs and CPPAs |  |  | 7,771,000 | $ 2,366,000 |
Short-term royalty and commercial payment receivables |  |  | 9,819,000 |  | $ 14,215,000
Affitech |  |  |  |  |
Agreements |  |  |  |  |
Reduction in short-term royalty receivable balance due to receipt of payment |  |  | 7,396,000 |  |
Recognition of contingent consideration, Short-Term |  |  | 3,000,000 |  |
Affitech | Commercial Payment Purchase Agreement |  |  |  |  |
Agreements |  |  |  |  |
Payments of consideration under RPAs, AAAs and CPPAs | $ 6,000,000.0 |  | 6,000,000.0 |  |
Period from each royalty payment date payment is due |  |  |  |  | 60 days
Maximum regulatory and commercial sales milestone payments | 20,000,000.0 |  |  |  |
Acquisition of royalty and commercial payment receivables, Long-Term | 14,000,000.0 |  |  |  |
Maximum commercial sales milestone payments | $ 12,000,000.0 |  | 3,000,000.0 |  |
Receipts under RPAs, AAAs and CPPAs |  |  | 7,400,000 |  |
Short-term royalty and commercial payment receivables |  |  | 7,800,000 |  | $ 12,200,000
Recognition of contingent consideration, Short-Term |  |  | 3,000,000.0 |  |
Recognition of contingent consideration, Long-Term |  |  |  |  | 6,000,000.0
Amount of allowance for credit losses |  |  | 0 |  | 0
Affitech | Commercial Payment Purchase Agreement | Faricimab (VABYSMO) |  |  |  |  |
Agreements |  |  |  |  |
Payments eligible to receive (as a percent) | 0.50% |  |  |  |
Commercial payment receivable term | 10 years |  |  |  |
Affitech | Commercial Payment Purchase Agreement | Faricimab (VABYSMO) | United States |  |  |  |  |
Agreements |  |  |  |  |
Payments of consideration under RPAs, AAAs and CPPAs |  | $ 5,000,000.0 |  |  |
Affitech | Commercial Payment Purchase Agreement | Faricimab (VABYSMO) | Europe |  |  |  |  |
Agreements |  |  |  |  |
Payments of consideration under RPAs, AAAs and CPPAs |  | $ 3,000,000.0 |  |  |
Affitech | Commercial Payment Purchase Agreement | Regulatory milestones |  |  |  |  |
Agreements |  |  |  |  |
Contingent consideration under RPAs, AAAs and CPPAs | $ 8,000,000.0 |  |  |  |
Affitech | Commercial Payment Purchase Agreement | Sales-based milestones, first and second |  |  |  |  |
Agreements |  |  |  |  |
Contingent consideration under RPAs, AAAs and CPPAs |  |  | 0 |  | $ 6,000,000.0
Affitech | Commercial Payment Purchase Agreement | Sales-based milestones, third |  |  |  |  |
Agreements |  |  |  |  |
Contingent consideration under RPAs, AAAs and CPPAs |  |  | 3,000,000.0 |  |
Short-term royalty and commercial payment receivables |  |  | $ 3,000,000.0 |  |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13 + Details
Name: | us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Period from each royalty payment date payment is due from customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | xoma_CommercialPaymentPeriodDue
Namespace Prefix: | xoma_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Term of commercial payment receivable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | xoma_CommercialPaymentReceivableTerm
Namespace Prefix: | xoma_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payments entity eligible to receive as a percentage of net sales. + References No definition available. + Details
Name: | xoma_CommercialSalesReceivablePercentageOnNetSales
Namespace Prefix: | xoma_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, assignment and assumption agreements, and commercial payment purchase agreements. Includes contingent consideration recognized under ASC 815 and measured at fair value as a current liability at the inception of the transaction. Also includes contingent consideration recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. + References No definition available. + Details
Name: | xoma_ContingentConsiderationUnderPurchaseAgreements
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Maximum amount payable on sales milestone. Contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. + References No definition available. + Details
Name: | xoma_MaximumPayableOnSalesMilestone
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Maximum payments to be made based upon achievement of regulatory or sales milestones. For regulatory milestones, contingent consideration is measured at fair value as a current liability at the inception of the transaction under ASC 815. For sales milestones, contingent consideration is recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. + References No definition available. + Details
Name: | xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments. + References No definition available. + Details
Name: | xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Decrease in short-term rights receivable due to receipt of current portion of royalty and commercial payments. + References No definition available. + Details
Name: | xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of cash inflow under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial Payment Purchase Agreements (CPPAs), classified as investing activities. Receipts may represent commercial payments attributable to net sales. + References No definition available. + Details
Name: | xoma_ReceiptsUnderAgreementsInvestingActivities
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Royalty and commercial payment receivables probable and reasonably estimable to be received within one year or the normal operating cycle, if longer. + References No definition available. + Details
Name: | xoma_RightsReceivableCurrent
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Increase in short-term rights receivable due to recognition of contingent consideration. + References No definition available. + Details
Name: | xoma_RoyaltyAndCommercialPaymentReceivableCurrentRecognitionOfContingentConsideration
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Increase in long-term rights receivable due to recognition of contingent consideration. + References No definition available. + Details
Name: | xoma_RoyaltyAndCommercialPaymentReceivableNonCurrentRecognitionOfContingentConsideration
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Increase in long term rights receivable due acquisition of royalty, interest and commercial payment rights. + References No definition available. + Details
Name: | xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xoma_CommercialPaymentPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_FaricimabProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=xoma_ContingentConsiderationRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=xoma_ContingentConsiderationSalesMilestonesOneAndTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=xoma_ContingentConsiderationSalesMilestonesThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |